Opportunities and challenges in drug development for pediatric cancers

TW Laetsch, SG DuBois, JG Bender, ME Macy… - Cancer discovery, 2021 - AACR
The use of targeted small-molecule therapeutics and immunotherapeutics has been limited
to date in pediatric oncology. Recently, the number of pediatric approvals has risen, and …
被引用次数：37 相关文章

Opportunities and Challenges in Drug Development for Pediatric Cancers

TW Laetsch, SG DuBois, JG Bender… - Cancer …, 2021 - pubmed.ncbi.nlm.nih.gov
The use of targeted small-molecule therapeutics and immunotherapeutics has been limited
to date in pediatric oncology. Recently, the number of pediatric approvals has risen, and …
[HTML] nih.gov

[HTML][HTML] Opportunities and Challenges in Drug Development for Pediatric Cancers

TW Laetsch, SG DuBois, JG Bender, ME Macy… - Cancer …, 2021 - ncbi.nlm.nih.gov
The use of targeted small molecule and immuno-therapeutics has been limited to date in
pediatric oncology. Recently, the number of pediatric approvals has risen and regulatory …

Opportunities and Challenges in Drug Development for Pediatric Cancers.

TW Laetsch, SG DuBois, JG Bender, ME Macy… - Cancer …, 2020 - europepmc.org
The use of targeted small molecule and immuno-therapeutics has been limited to date in
pediatric oncology. Recently, the number of pediatric approvals has risen and regulatory …